Diabetes Mellitus Under the Covid-19 Viral Pandemic.

Abstract

In 2020, the world faced an unprecedented health challenge associated with the invasion of the novel coronavirus SARS COV-2. This is also a challenge for healthcare systems around the world. The most vulnerable in these conditions were patients with diabetes mellitus (DM) due to the peculiarities of their immune status and immune response to a viral attack, due to excessively high activity of the virus in conditions of hyperglycemia, due to comorbidity and obesity, which often accompany the course of DM. The severe course of the COVID-19 disease requires a mandatory review of the usual glucose-lowering therapy. It remains extremely important to maintain optimal glycemic control and prevent the development of ketoacidosis, and therefore, in most cases, insulin becomes the priority drug for glycemic control. The search for new drugs to combat coronavirus infection continues, and new randomized clinical trials of drugs are starting. Innovative antidiabetic drugs are also being tested as candidates for potentially effective drugs to combat coronavirus.[1,2,3,4]